These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 35923421)

  • 1. Type 2 inflammation in asthma and other airway diseases.
    Maspero J; Adir Y; Al-Ahmad M; Celis-Preciado CA; Colodenco FD; Giavina-Bianchi P; Lababidi H; Ledanois O; Mahoub B; Perng DW; Vazquez JC; Yorgancioglu A
    ERJ Open Res; 2022 Jul; 8(3):. PubMed ID: 35923421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait!
    Bel EH; Ten Brinke A
    Chest; 2017 Dec; 152(6):1276-1282. PubMed ID: 28583618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innate Lymphoid Cells in Airway Inflammation.
    Asghar Pasha M; Yang Q
    Adv Exp Med Biol; 2021; 1303():183-191. PubMed ID: 33788194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 2 innate lymphoid cells: at the cross-roads in allergic asthma.
    van Rijt L; von Richthofen H; van Ree R
    Semin Immunopathol; 2016 Jul; 38(4):483-96. PubMed ID: 26965110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eosinophilia Induced by Blocking the IL-4/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes.
    Olaguibel JM; Sastre J; Rodríguez JM; Del Pozo V
    J Investig Allergol Clin Immunol; 2022 Jun; 32(3):165-180. PubMed ID: 35522053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic mechanisms in asthma.
    Boonpiyathad T; Sözener ZC; Satitsuksanoa P; Akdis CA
    Semin Immunol; 2019 Dec; 46():101333. PubMed ID: 31703832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab.
    Cheng SL
    Life (Basel); 2021 Jul; 11(8):. PubMed ID: 34440488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulating ILC2 function for treatment of type 2 airway diseases.
    Huang YA; Strohm A; Doherty T
    Curr Trends Immunol; 2022; 23():85-90. PubMed ID: 37396395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Analysis of Biologic Therapies in Patients With Asthma and Chronic Rhinosinusitis.
    Gore MR; Fung E; Tao M
    Cureus; 2022 Oct; 14(10):e30017. PubMed ID: 36225247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Airway mycosis in allergic airway disease.
    Li E; Knight JM; Wu Y; Luong A; Rodriguez A; Kheradmand F; Corry DB
    Adv Immunol; 2019; 142():85-140. PubMed ID: 31296304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Targeted Therapies for Uncontrolled Asthma.
    Corren J
    J Allergy Clin Immunol Pract; 2019; 7(5):1394-1403. PubMed ID: 31076057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary care of asthma: new options for severe eosinophilic asthma.
    Skolnik NS; Carnahan SP
    Curr Med Res Opin; 2019 Jul; 35(7):1309-1318. PubMed ID: 30880484
    [No Abstract]   [Full Text] [Related]  

  • 13. Eosinophilic airway diseases: basic science, clinical manifestations and future challenges.
    Janson C; Bjermer L; Lehtimäki L; Kankaanranta H; Karjalainen J; Altraja A; Yasinska V; Aarli B; Rådinger M; Hellgren J; Lofdahl M; Howarth PH; Porsbjerg C
    Eur Clin Respir J; 2022; 9(1):2040707. PubMed ID: 35251534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.
    Pelaia C; Vatrella A; Bruni A; Terracciano R; Pelaia G
    Drug Des Devel Ther; 2018; 12():619-628. PubMed ID: 29606855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Collaborative interactions between type 2 innate lymphoid cells and antigen-specific CD4+ Th2 cells exacerbate murine allergic airway diseases with prominent eosinophilia.
    Liu B; Lee JB; Chen CY; Hershey GK; Wang YH
    J Immunol; 2015 Apr; 194(8):3583-93. PubMed ID: 25780046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of eosinophilic inflammation is independent of B-T cell interaction in a chronic house dust mite-driven asthma model.
    Vroman H; Bergen IM; Li BW; van Hulst JA; Lukkes M; van Uden D; Hendriks RW; Kool M
    Clin Exp Allergy; 2017 Apr; 47(4):551-564. PubMed ID: 27743410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Monoclonal Antibodies on Airway Smooth Muscle Contractility in Asthma: A Systematic Review.
    Calzetta L; Aiello M; Frizzelli A; Bertorelli G; Ritondo BL; Rogliani P; Chetta A
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cells are necessary for ILC2 activation in house dust mite-induced allergic airway inflammation in mice.
    Li BW; de Bruijn MJ; Tindemans I; Lukkes M; KleinJan A; Hoogsteden HC; Hendriks RW
    Eur J Immunol; 2016 Jun; 46(6):1392-403. PubMed ID: 27062360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Targets for Biological Therapies of Severe Asthma.
    Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
    Front Immunol; 2020; 11():603312. PubMed ID: 33329598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.